ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 10, 2017
Dividend Increases/Decreases for the Week Ending November 10
Let's take a look at companies raising/lowering their dividends this week.
Nov 8, 2017
Alphabet Soars to New Highs, Priceline Tumbles
Image shown: Alphabet’s shares have been surging higher, and we think the move is justified on the basis of our fair value estimate. Best Ideas Newsletter portfolio idea Alphabet continues to drive tremendous fundamental performance via its strength in search, and its pipeline of new opportunities may offer another blockbuster product in the years ahead. Priceline, on the other hand, has been under selling pressure following a disappointing bottom-line outlook for the fourth quarter.
Nov 7, 2017
Michael Kors’ Stock Surges; Market Overreacts to Hanesbrands' Results
Image shown: Shares of Michael Kors have been rocketing higher recently. The stock is rated 9 on the Valuentum Buying Index. The sole 9 rating on the Valuentum Buying Index has had a very nice couple of months recently. Meanwhile, Hanesbrands is feeling the wrath of considerable selling pressure, and we don't think it is justified.
Nov 7, 2017
Analysis of Spark Energy (SPKE) and Brighthouse Financial (BHF)
Let's talk about an extremely risky microcap energy equity and a unique potential value opportunity in the insurance industry, Brighthouse Financial, the spinoff of Metlife.
Nov 3, 2017
Dividend Increases/Decreases for the Week Ending November 3
Let's take a look at companies raising/lowering their dividends this week.
Nov 3, 2017
Add the New High Yield Dividend Newsletter! It’s Purely Incremental
The Dividend Growth Newsletter is part of a premium, adviser, or institutional membership to Valuentum, but the new High Yield Dividend Newsletter is purely incremental. Add it to any membership today! Update: The $400/year offer for the High Yield Dividend Newsletter has passed, but you can still sign up for $500/year before the end of the year ($1,000/year thereafter). Lock in the savings!
Nov 2, 2017
The Price of Good Investment Research?
Photo credit: Phlebotomy Tech; Thomas Haynie Skimping on research could cost you big when the you-know-what hits the fan. Research firms are reportedly charging as much as $5,000 per hour for one-on-one meetings with top analysts. Access to basic research is now being priced at $40,000 a year at some firms.
Nov 2, 2017
Valuentum's November Edition of Its Dividend Growth Newsletter
Image Source: Chris Potter. The link to download the November edition of the Dividend Growth Newsletter can be found in this article.
Oct 31, 2017
CVS Health Under Review – Hit by a Storm of Negativity
Image Source: Mike Mozart. We are putting the fair value estimate of CVS Health under review while we re-evaluate the competitive environment and reassess the company’s appetite for leverage, which could impact dividend health.
Oct 31, 2017
Novartis Gearing Up for Growth
 Image Source: Novartis. Dividend Growth Newsletter portfolio idea Novartis continues to grow its free cash flow stream while producing a string of products still in the infancy of their respective growth curves. The pharma/biotech realm remains bedeviled with patent issues that can disrupt cash flow generation once protection is lost, causing us to look for companies positioned for a fresh leg of growth. To that end, let’s take a look at Novartis’ pipeline, near-term potential, and how it relates to its dividend health.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.